Search Results - richard+roden

6 Results

Sort By:

Hybridoma expressing anti-RG-1 mAb for the study of human papillomavirus L2

Technology DescriptionJHU scientists generated a hybridoma expressing a monoclonal antibody, RG-1, that binds to highly conserved L2 residues and neutralizes human papillomavirus 16 (HPV16) and HPV18. Passive immunotherapy with RG-1 was protective in mice. Antiserum to the HPV16 L2 peptide comprising conserved residues neutralized pseudoviruses HPV5,...

Published: 5/9/2024 | Inventor(s): Ratish Gambhira, Richard Roden

Keywords(s): Antibodies, Basic Research Biomarker, Cell Model, Discovery/Research Tools, Hybridomas, In Vitro Research Tool, Monoclonal Antibodies, Research Reagent

Category(s): Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools

Anti-cancer "Spirocyclic-guanidine Compounds" and Uses Thereof

Unmet Need / Invention Novelty: Currently available anti-cancer proteasome inhibitors are highly effective against liquid tumors, however, resistance develops. Furthermore, available proteasome inhibitors are not effective against solid tumors. There is an unmet need to develop anti-cancer proteasome inhibitors that overcome these limitations. Technical...

Published: 5/10/2024 | Inventor(s): Richard Roden, Ravi Anchoori

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Novel Bis-benzylidine Piperidone-based Proteasome Inhibitors with Anticancer Activity

Unmet NeedA hallmark of many human cancers is the proteasomal degradation of tumor suppressor proteins, leading to apoptosis arrest and sustained cell proliferation. Yet, to date, the therapeutic use of proteasome inhibitors is impeded by the grave side effects and emergence of disease resistance. This invention provides the novel small molecule proteasome...

Published: 5/9/2024 | Inventor(s): Balasubramanyam Karanam, Ravi Anchoori, Richard Roden

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Candidate Small Molecule Proteasome Inhibitors with Antitumor Properties

Unmet NeedCancer cells differ critically from normal cells, e.g., higher metabolic rates. Proteasomes play a pivotal role in managing excessive metabolism and maintaining protein homeostasis, as the continued over-accumulation of mis-folded proteins is toxic to cells.Several proteasome inhibitors have proven efficacious against hematologic malignancies,...

Published: 5/10/2024 | Inventor(s): Ravi Anchoori, Richard Roden

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules

DNA Constructs to Make Papillomavirus Pseudovirions for HPV Types

These are codon-optimized DNA constructs for the expression of different HPV types major capsid protein, L1 and minor capsid protein, L2, in the vector pVITRO.This Material is also available at Addgene: https://www.addgene.org/Richard_Roden/Related Publication:■ Vaccine. 2010 Jun 17; 28(28): 4478–4486. ■

Published: 5/9/2024 | Inventor(s): Richard Roden

Keywords(s): Basic Research Biomarker, Cloning Reagents, Discovery/Research Tools, Disease Indication, Human Papillomavirus, Human Papillomavirus (HPV), Infectious Diseases, Plasmid, Research Reagent, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Human Papillomavirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Research Tools > Vectors & Plasmids, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Research Tools

Unexpected Cross-neutralization of Cutaneous & Mucosal Papillomavirus Types with Anti-Sera to a Novel L2 Epitopes

C04603: Unexpected Cross-neutralization of Cutaneous & Mucosal Papillomavirus Types with Anti-Sera to a Novel Epitopes Technical Details: High risk Human Papillomavirus (HPV) infection is a common cause of cervical cancer. Researchers at JHU have found that vaccination with the N terminus of HPV16 and bovine papillomavirus 1 can induce cross...

Published: 5/9/2024 | Inventor(s): John Schiller, Douglas Lowy, Diane Pastrana, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Cervical Cancer, Disease Indication, Human Papillomavirus (HPV), Infectious Diseases, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Cervical Cancer, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Human Papillomavirus (HPV)